{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [{"AbstractText": ["La modulation immunitaire provoqu\u00e9e par Celacade (Vasogen Inc., Canada) diminue la mortalit\u00e9 et les hospitalisations dues \u00e0 l\u2019insuffisance cardiaque chez l\u2019homme.", "L\u2019\u00e9tude avait pour but d\u2019examiner les effets de Celacade, chez des rats, sur l\u2019expression des cytokines durant la phase aigu\u00eb apr\u00e8s la ligature d\u2019une art\u00e8re coronaire, sur les dimensions du c\u0153ur apr\u00e8s un infarctus du myocarde (IM) et sur le fonctionnement systolique et diastolique du muscle cardiaque apr\u00e8s un IM.", "Celacade a \u00e9t\u00e9 administr\u00e9 14 jours avant la ligature de l\u2019art\u00e8re coronaire et tous les mois apr\u00e8s l\u2019intervention chirurgicale. L\u2019expression des cytokines a \u00e9t\u00e9 mesur\u00e9e dans le tissu cardiaque au 1<sup>er</sup> et au 7<sup>e</sup> jour selon la technique ELISA chez des rats t\u00e9moins et des rats ayant subi un IM (avec ou sans traitement par Celacade). Des \u00e9chocardiogrammes ont \u00e9t\u00e9 produits en s\u00e9rie pendant 16 semaines. La force et la longueur des sarcom\u00e8res (LS) ont \u00e9t\u00e9 mesur\u00e9es au moyen d\u2019une jauge de contrainte et d\u2019un instrument de diffraction au laser dans des trab\u00e9cules isol\u00e9es de ventricule droit \u00e0 la 16<sup>e</sup> semaine. L\u2019effet inotropique de la stimulation sur la force a \u00e9t\u00e9 quantifi\u00e9 selon la formule suivante : F<sub>5 Hz/0,5 Hz</sub>, et le dysfonctionnement diastolique, comme la racine carr\u00e9e moyenne des fluctuations spontan\u00e9es de la LS.", "Celacade a inhib\u00e9 la production du facteur de croissance transformant b\u00eata-1 dans la zone infarcie au 7<sup>e</sup> jour (191,6 \u00b1 22,6 pg/mg contre [c.] 275,4 \u00b1 30,1 pg/mg; P < 0,05), mais n\u2019a pas diminu\u00e9 la dilatation du c\u0153ur apr\u00e8s un IM. Celacade a \u00e9galement r\u00e9tabli l\u2019inotropisme positif de la stimulation apr\u00e8s un IM (F<sub>5 Hz/0,5 Hz</sub> avec Celacade : 219,1 \u00b1 46,7 %; IM : 148,1 \u00b1 27,1 % [P < 0,05 comparativement \u00e0 211,4 \u00b1 37,9 % chez les t\u00e9moins]). Celacade a aussi att\u00e9nu\u00e9 le dysfonctionnement diastolique apr\u00e8s un IM (racine carr\u00e9e moyenne des fluctuations spontan\u00e9es de la LS : 121 \u00b1 15 % et 143 \u00b1 19 % avec Celacade c. 184 \u00b1 19 % et 190 \u00b1 26 % sans Celacade \u00e0 26\u00b0C et \u00e0 36\u00b0C, respectivement) par rapport aux t\u00e9moins (100 %; P < 0,05).", "Celacade amoindrit la surexpression du facteur de croissance transformant b\u00eata-1 durant la phase aigu\u00eb de l\u2019IM chez des rats, mais ne pr\u00e9vient pas la dilatation chronique du c\u0153ur. Celacade r\u00e9tablit l\u2019effet inotropique positif de la fr\u00e9quence accrue de stimulation dans des trab\u00e9cules de ventricule droit de rats ayant subi un IM \u00e9tendu et att\u00e9nue \u00e9galement le dysfonctionnement diastolique."]}], "OtherID": [], "PMID": "19584980", "DateCompleted": {"Year": "2009", "Month": "07", "Day": "31"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "20"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "1916-7075", "JournalIssue": {"Volume": "25", "Issue": "7", "PubDate": {"Year": "2009", "Month": "Jul"}}, "Title": "The Canadian journal of cardiology", "ISOAbbreviation": "Can J Cardiol"}, "ArticleTitle": "Effects of therapy using the Celacade system on structural and functional cardiac remodelling in rats following myocardial infarction.", "Pagination": {"StartPage": "e241", "EndPage": "e247", "MedlinePgn": "e241-7"}, "Abstract": {"AbstractText": ["Immune modulation by the Celacade system (Vasogen Inc, Canada) decreases mortality and hospitalization in human heart failure.", "To study the effects of Celacade in rats on acute cytokine expression after coronary artery ligation, cardiac dimensions following myocardial infarction (MI), and systolic and diastolic function of cardiac muscle in MI.", "Celacade treatment was administered 14 days before coronary artery ligation and monthly after the surgery. Cytokine expression in cardiac tissue was measured on days 1 and 7 by ELISA in sham rats and in rats with MI (with or without Celacade treatment). Echocardiograms were obtained serially for 16 weeks. Force and sarcomere length (SL) were measured by strain gauge and laser diffraction in isolated right ventricle trabeculas at 16 weeks. The inotropic effect of pacing on force was quantified as F5 Hz/0.5 Hz. Diastolic dysfunction was quantified as the root mean square of spontaneous SL fluctuations.", "Celacade inhibited transforming growth factor beta-1 production in the infarct area on day 7 (191.6+/-22.6 pg/mg versus 275.4+/-30.1 pg/mg; P<0.05), but did not attenuate cardiac dilation in MI. Celacade restored positive inotropism of pacing in MI (F5 Hz/0.5 Hz in Celacade, 219.1+/-46.7%; MI, 148.1+/-27.1% [P<0.05 compared with 211.4+/-37.9% in sham]). Celacade reduced diastolic dysfunction in MI (root mean square of spontaneous SL fluctuations: 121+/-15% and 143+/-19% with Celacade versus 184+/-19% and 190+/-26% without Celacade at 26 degrees C and 36 degrees C, respectively) compared with sham (100%; P<0.05).", "Celacade reduces the increase of transforming growth factor beta-1 expression during the acute stage of MI in rats, but does not prevent chronic cardiac dilation. Celacade restores the positive inotropic effect of increased pacing rate in trabeculas from rat right ventricles with large MIs and reduces diastolic dysfunction."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Sciences, Libin Cardiovascular Institute of Alberta, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1."}], "Identifier": [], "LastName": "Zhang", "ForeName": "Mei Luo", "Initials": "ML"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Mei", "ForeName": "Jie", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Archer", "ForeName": "Lori Anne", "Initials": "LA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Obayashi", "ForeName": "Masakazu", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Diao", "ForeName": "Ni", "Initials": "N"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Stuyvers", "ForeName": "Bruno", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "ter Keurs", "ForeName": "Henk E D J", "Initials": "HE"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Can J Cardiol", "NlmUniqueID": "8510280", "ISSNLinking": "0828-282X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-6"}, {"RegistryNumber": "0", "NameOfSubstance": "Transforming Growth Factor beta1"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Analysis of Variance"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Hot Temperature"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Interleukin-6"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Myocardial Contraction"}, {"QualifierName": ["diagnostic imaging", "immunology", "therapy"], "DescriptorName": "Myocardial Infarction"}, {"QualifierName": ["immunology", "pathology"], "DescriptorName": "Myocardium"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Inbred BN"}, {"QualifierName": [], "DescriptorName": "Rats, Inbred Lew"}, {"QualifierName": [], "DescriptorName": "Time Factors"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Transforming Growth Factor beta1"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Tumor Necrosis Factor-alpha"}, {"QualifierName": [], "DescriptorName": "Ultrasonography"}, {"QualifierName": [], "DescriptorName": "Ultraviolet Rays"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Davidoff AW, Boyden PA, Schwartz K, et al. Congestive heart failure after myocardial infarction in the rat: Cardiac force and spontaneous sarcomere activity. Ann N Y Acad Sci. 2004;1015:84\u201395.", "ArticleIdList": ["15201151"]}, {"Citation": "Obayashi M, Xiao BL, Stuyvers BD, et al. Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. Cardiovasc Res. 2006;69:140\u201351.", "ArticleIdList": ["16112660"]}, {"Citation": "Tremblay J, Chen HF, Peng JZ, et al. Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. Transplantation. 2002;74:1425\u201333.", "ArticleIdList": ["12451244"]}, {"Citation": "Babaei S, Stewart DJ, Picard P, Monge JC. Effects of VasoCare therapy on the initiation and progression of atherosclerosis. Atherosclerosis. 2002;162:45\u201353.", "ArticleIdList": ["11947896"]}, {"Citation": "Torre-Amione G, Sestier FO, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure \u2013 results of a randomized, controlled, phase II trial. J Am Coll Cardiol. 2004;44:1181\u20136.", "ArticleIdList": ["15364317"]}, {"Citation": "Coletta AP, Nikitin N, Clark AL, Cleland JG. Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure. Eur J Heart Fail. 2003;5:95\u20139.", "ArticleIdList": ["12559221"]}, {"Citation": "McGrath C, Robb R, Lucas AJ, et al. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg. 2002;23:381\u20137.", "ArticleIdList": ["12027463"]}, {"Citation": "Cooke ED, Pockley AG, Tucker AT, Kirby JD, Bolton AE. Treatment of severe Raynaud\u2019s syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy. Int Angiol. 1997;16:250\u20134.", "ArticleIdList": ["9543222"]}, {"Citation": "Johns TNP, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surg. 1954;140:675\u201382.", "ArticleIdList": ["PMC1609650", "13208115"]}, {"Citation": "Francis J, Chu Y, Johnson AK, Weiss RM, Felder RB. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol. 2004;286:H2264\u201371.", "ArticleIdList": ["15148057"]}, {"Citation": "Davidoff AW.Cardiac muscle function after coronary artery ligation in rat. PhD thesis, University of Calgary, 2002"}, {"Citation": "Terkeurs HEDJ, Rijnsburger WH, Vanheuningen R, Nagelsmit MJ. Tension development and sarcomere-length in rat cardiac trabeculae \u2013 evidence of length-dependent activation. Circ Res. 1980;46:703\u201314.", "ArticleIdList": ["7363419"]}, {"Citation": "Stuyvers BD, Miura M, Ter Keurs HE. Dynamics of viscoelastic properties of rat cardiac sarcomeres during the diastolic interval: Involvement of Ca2+ J Physiol. 1997;502:661\u201377.", "ArticleIdList": ["PMC1159536", "9279816"]}, {"Citation": "Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 1991;260:H1406\u201314.", "ArticleIdList": ["2035662"]}, {"Citation": "Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell. 2000;101:365\u201376.", "ArticleIdList": ["10830164"]}, {"Citation": "Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94:e61\u2013e70.", "ArticleIdList": ["15016728"]}, {"Citation": "Xiao B, Zhong G, Obayashi M, et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J. 2006;396:7\u201316.", "ArticleIdList": ["PMC1449991", "16483256"]}, {"Citation": "Yano M, Ono K, Ohkusa T, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000;102:2131\u20136.", "ArticleIdList": ["11044432"]}, {"Citation": "Tokuhisa T, Yano M, Obayashi M, et al. AT1 receptor antagonist restores cardiac ryanodine receptor function, rendering isoproterenol-induced failing heart less susceptible to Ca2+-leak induced by oxidative stress. Circ J. 2006;70:777\u201386.", "ArticleIdList": ["16723803"]}, {"Citation": "Holubarsch C, Ruf T, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation. 1996;94:683\u20139.", "ArticleIdList": ["8772688"]}, {"Citation": "Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. Eur J Pharmacol. 2004;500:73\u201386.", "ArticleIdList": ["15464022"]}, {"Citation": "Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743\u201350.", "ArticleIdList": ["1572031"]}, {"Citation": "Schouten VJ, Ter Keurs HE. The force-frequency relationship in rat myocardium. The influence of muscle dimensions. Pflugers Arch. 1986;407:14\u20137.", "ArticleIdList": ["3737379"]}, {"Citation": "Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res. 2000;87:275\u201381.", "ArticleIdList": ["10948060"]}, {"Citation": "Hund TJ, Rudy Y. A role for calcium/calmodulin-dependent protein kinase II in cardiac disease and arrhythmia. Handb Exp Pharmacol. 2006:201\u2013220.", "ArticleIdList": ["16610345"]}, {"Citation": "Deten A, Zimmer HG. Heart function and cytokine expression is similar in mice and rats after myocardial infarction but differences occur in TNF alpha expression. Pflug Arch Eur J Phy. 2002;445:289\u201396.", "ArticleIdList": ["12457250"]}, {"Citation": "Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res. 2002;55:329\u201340.", "ArticleIdList": ["12123772"]}, {"Citation": "Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492\u20138.", "ArticleIdList": ["10086975"]}, {"Citation": "Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286\u201392.", "ArticleIdList": ["7935686"]}, {"Citation": "Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 2004;64:526\u201335.", "ArticleIdList": ["15537506"]}, {"Citation": "Okada H, Takemura G, Kosai K, et al. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation. 2005;111:2430\u20137.", "ArticleIdList": ["15867170"]}]}], "History": [{"Year": "2009", "Month": "7", "Day": "9", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "7", "Day": "9", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "8", "Day": "1", "Hour": "9", "Minute": "0"}, {"Year": "2010", "Month": "7", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["19584980", "PMC2723034", "10.1016/s0828-282x(09)70510-0", "S0828-282X(09)70510-0"]}}], "PubmedBookArticle": []}